Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
GEN Roundup: Multiplex Immunoassays Bring the Array, Not the Disarray
Get Multiplex Immunoassay Advice from GEN's Expert Panel
FDA: Too Restrictive?
In a debate held on May 8, 2013, major thinkers argued over whether or not the FDA is failing its mandate of protecting the public health, as its approval processes can slow the process of bringing new treatments to market. The debate featured a poll asking participants if they agree with the statement “The FDA’s caution is hazardous to our health.” The results: before the debate, 24% were in favor of that statement, 32% were against it, and 44% were undecided; after the debate, 53% were in favor, 38% were against it, and 9% were undecided. Now, we’re asking GEN readers a similar question.